ArticleBlood2016
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 108 citations in OpenAlex.
- Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.Blood advances · 2026Article
- Article
- Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).International journal of oncology · 2026Review
- Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.Blood advances · 2026Article
- CAR-T therapy for autoimmune rheumatic diseases: navigating clinical frontiers between breakthroughs and uncertainties.Clinical and experimental medicine · 2026Review
- Exploring the Role of B-Cell Biotherapy in Myasthenia Gravis from a Genetic Perspective: A Mendelian Randomization Study.Molecular neurobiology · 2025Article
- Targeting CD37 promotes macrophage-dependent phagocytosis of multiple cancer cell types and facilitates tumor clearance in mice.Nature communications · 2025Article
- Amino acid-based risk stratification model improves prognostic precision in diffuse large B-cell lymphoma.Cancer cell international · 2025Article
- Tumor Microenvironment, Inflammation, and Inflammatory Prognostic Indices in Diffuse Large B-Cell Lymphomas: A Narrative Review.International journal of molecular sciences · 2025Review
- CD151 interacts with integrin beta 2 in B cell lymphomas.Cellular and molecular life sciences : CMLS · 2025Article
- Activatable Sulfur Dioxide Nanosonosensitizer Enables Precisely Controllable Sono-Gaseous Checkpoint Trimodal Therapy for Orthotopic Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Interactions with and activation of immune cells by CD41aFrontiers in immunology · 2025Article
- PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.Blood advances · 2024Article
- Multimodal AI/ML for discovering novel biomarkers and predicting disease using multi-omics profiles of patients with cardiovascular diseases.Scientific reports · 2024Article
- Diagnostic and prognostic significance of tetraspanin 6 and its role in facilitating glioma progression.European journal of medical research · 2024Article
- T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- N-Glycosylation-dependent regulation of immune-specific tetraspanins CD37 and CD53.Biophysical journal · 2024Article
- Tetraspanin proteins in membrane remodeling processes.Journal of cell science · 2024Review
- CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.Cell reports. Medicine · 2024Article
- Transforming toxins into treatments: the revolutionary role of α-amanitin in cancer therapy.Archives of toxicology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
32 authors at 20 institutions in 9 countries.
Zijun Y Xu-MonetteDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ling LiDepartment of Oncology, The First Affiliated Hospital Zhengzhou University, Zhengzhou, China.
John C ByrdDepartment of Hematology and Oncology, The Ohio State University, Columbus, OH.
Kausar J JabbarDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ganiraju C ManyamDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Charlotte Maria de WindeRadboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Michiel van den BrandRadboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Alexandar TzankovUniversity Hospital, Basel, Switzerland.
Carlo ViscoSan Bortolo Hospital, Vicenza, Italy.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Karen DybkaerAalborg University Hospital, Aalborg, Denmark.
April ChiuMemorial Sloan Kettering Cancer Center, New York, NY.
Attilio OraziDepartment of Pathology, Weill Medical College of Cornell University, New York, NY.
Youli ZuDepartment of Pathology, The Methodist Hospital, Houston, TX.
Govind BhagatDepartment of Pathology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY.
Kristy L RichardsDepartment of Hematology and Oncology, University of North Carolina School of Medicine, Chapel Hill, NC.
Eric D HsiCleveland Clinic, Cleveland, OH.
William W L ChoiLi Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Jooryung HuhAsan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
Maurilio PonzoniSan Raffaele H. Scientific Institute, Milan, Italy.
Andrés J M FerreriSan Raffaele H. Scientific Institute, Milan, Italy.
Michael B MøllerOdense University Hospital, Odense, Denmark.
Ben M ParsonsGundersen Lutheran Health System, La Crosse, WI.
Jane N WinterFeinberg School of Medicine, Northwestern University, Chicago, IL.
Michael WangDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Frederick B HagemeisterDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Miguel A PirisHospital Universitario Marqués de Valdecilla, Santander, Spain.
J Han van KriekenRadboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Yong LiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; and.
Annemiek B van SprielRadboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Ken H YoungDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USRadboud University Nijmegen · NLSan Raffaele University of Rome · ITAalborg University Hospital · DKAsan Medical Center · KRChinese University of Hong Kong · CNCleveland Clinic · USCleveland Clinic Lerner College of Medicine · USColumbia University Irving Medical Center · USCornell University · USFirst Affiliated Hospital of Zhengzhou University · CNGundersen Health System · USMarqués de Valdecilla University Hospital · ESMemorial Sloan Kettering Cancer Center · USMethodist Hospital · USNorthwestern University · USOdense University Hospital · DKOspedale San Bortolo · ITRadboud University Medical Center · NLThe Ohio State University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9MP4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1MConvergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental CoR01CA138688 · NCI · UNIVERSITY OF LOUISVILLE · PI LI, YONG · 2009 to 2017
$2.9MMYC as a Biomarker in Aggressive Non-Hodgkin LymphomaR01CA187415 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LI, YONG · 2015 to 2019
$2.2MUT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2009 to 2011
$1.5MNCI NIH HHS P30 CA016672NCI NIH HHS P30 CA060553NCI NIH HHS P50 CA136411NCI NIH HHS P50 CA142509NCI NIH HHS R01 CA138688NCI NIH HHS R01 CA187415
Abstract
CD37 (tetraspanin TSPAN26) is a B-cell surface antigen widely expressed on mature B cells. CD37 is involved in immune regulation and tumor suppression but its function has not been fully elucidated. We assessed CD37 expression in de novo diffuse large B-cell lymphoma (DLBCL), and investigated its clinical and biologic significance in 773 patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and 231 patients treated with CHOP. We found that CD37 loss (CD37
Indexed as
Antigens, CD20Antigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsB-LymphocytesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGerminal CenterHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedModels, BiologicalMultivariate AnalysisMutationNF-kappa BAntigens, CD20Antigens, NeoplasmCD37 protein, humanNF-kappa BPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-mycRNA, MessengerTetraspaninsTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.